Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 16;12:727704. doi: 10.3389/fphar.2021.727704

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhu, Wang, Cai, Pan, Lin, Zhang, Chen, Leng, He, Zhou, Wu, Fang, Li, Li, Liu and Lai.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

NAT2 is a potential target of vitamin D₃ against CRC based on a network pharmacological analysis. (A) Volcano map of 3388 DEGs (including 2,079 upregulated genes and 1,309 downregulated genes) from TCGA. Red: upregulation; green: downregulation; log2 FC: log2 fold change. (B) UpSet plot showing predicted cancer target genes among DEGs by six databases. (C) Venn plot showing 411 predicted vitamin D₃ targets from 4 databases. (D) Venn plot showing 29 overlapping targets between vitamin D₃– and CRC-related genes. (E) PPI network of drug cancer targets. Pink: overlapping targets; blue: amplified targets. (F) Functionally enriched GO terms and KEGG pathway analysis of the overlapping targets. The bars represent the percentage of associated genes per term. (G,H) The correlation between NAT2 expression and overall survival (G) or disease-free survival (H) in CRC patients from GEPIA.